411 related articles for article (PubMed ID: 32322464)
1. Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders.
Deng H; Li W
Acta Pharm Sin B; 2020 Apr; 10(4):582-602. PubMed ID: 32322464
[TBL] [Abstract][Full Text] [Related]
2. Cross-validated stable-isotope dilution GC-MS and LC-MS/MS assays for monoacylglycerol lipase (MAGL) activity by measuring arachidonic acid released from the endocannabinoid 2-arachidonoyl glycerol.
Kayacelebi AA; Schauerte C; Kling K; Herbers J; Beckmann B; Engeli S; Jordan J; Zoerner AA; Tsikas D
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1047():151-159. PubMed ID: 27511795
[TBL] [Abstract][Full Text] [Related]
3. Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.
Chicca A; Arena C; Manera C
Recent Pat CNS Drug Discov; 2016; 10(2):122-141. PubMed ID: 27630088
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of 2-acylglycerol in rabbit and human platelets. Involvement of monoacylglycerol lipase and fatty acid amide hydrolase.
Gkini E; Anagnostopoulos D; Mavri-Vavayianni M; Siafaka-Kapadai A
Platelets; 2009 Sep; 20(6):376-85. PubMed ID: 19811221
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors.
Di Stefano M; Masoni S; Bononi G; Poli G; Galati S; Gado F; Manzi S; Vagaggini C; Brai A; Caligiuri I; Asif K; Rizzolio F; Macchia M; Chicca A; Sodi A; Di Bussolo V; Minutolo F; Meier P; Gertsch J; Granchi C; Dreassi E; Tuccinardi T
Eur J Med Chem; 2024 Jan; 263():115916. PubMed ID: 37976705
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of monoacylglycerol lipase inhibitors.
Mulvihill MM; Nomura DK
Life Sci; 2013 Mar; 92(8-9):492-7. PubMed ID: 23142242
[TBL] [Abstract][Full Text] [Related]
8. New Disulfiram Derivatives as MAGL-Selective Inhibitors.
Omran Z
Molecules; 2021 May; 26(11):. PubMed ID: 34070869
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.
Ghafouri N; Tiger G; Razdan RK; Mahadevan A; Pertwee RG; Martin BR; Fowler CJ
Br J Pharmacol; 2004 Nov; 143(6):774-84. PubMed ID: 15492019
[TBL] [Abstract][Full Text] [Related]
10. WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms.
Wen J; Jones M; Tanaka M; Selvaraj P; Symes AJ; Cox B; Zhang Y
J Neuroinflammation; 2018 Jan; 15(1):9. PubMed ID: 29310667
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of carbamate derivatives as fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
Jaiswal S; Gupta G; Ayyannan SR
Arch Pharm (Weinheim); 2022 Nov; 355(11):e2200081. PubMed ID: 35924298
[TBL] [Abstract][Full Text] [Related]
12. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue.
Pasquarelli N; Porazik C; Hanselmann J; Weydt P; Ferger B; Witting A
Neuropharmacology; 2015 Apr; 91():148-56. PubMed ID: 25497453
[TBL] [Abstract][Full Text] [Related]
13. Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.
Aly E; Masocha W
IBRO Neurosci Rep; 2021 Jun; 10():109-118. PubMed ID: 34179865
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor.
Wyatt RM; Fraser I; Welty N; Lord B; Wennerholm M; Sutton S; Ameriks MK; Dugovic C; Yun S; White A; Nguyen L; Koudriakova T; Tian G; Suarez J; Szewczuk L; Bonnette W; Ahn K; Ghosh B; Flores CM; Connolly PJ; Zhu B; Macielag MJ; Brandt MR; Chevalier K; Zhang SP; Lovenberg T; Bonaventure P
J Pharmacol Exp Ther; 2020 Mar; 372(3):339-353. PubMed ID: 31818916
[TBL] [Abstract][Full Text] [Related]
15. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
[TBL] [Abstract][Full Text] [Related]
16. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis.
Bisogno T; Cascio MG; Saha B; Mahadevan A; Urbani P; Minassi A; Appendino G; Saturnino C; Martin B; Razdan R; Di Marzo V
Biochim Biophys Acta; 2006 Feb; 1761(2):205-12. PubMed ID: 16466961
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Potential of Small-Molecule Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase.
Jaiswal S; Ayyannan SR
ChemMedChem; 2021 Jul; 16(14):2172-2187. PubMed ID: 33834617
[TBL] [Abstract][Full Text] [Related]
18. Human leukocytes differentially express endocannabinoid-glycerol lipases and hydrolyze 2-arachidonoyl-glycerol and its metabolites from the 15-lipoxygenase and cyclooxygenase pathways.
Turcotte C; Dumais É; Archambault AS; Martin C; Blanchet MR; Bissonnette É; Boulet LP; Laviolette M; Di Marzo V; Flamand N
J Leukoc Biol; 2019 Dec; 106(6):1337-1347. PubMed ID: 31556464
[TBL] [Abstract][Full Text] [Related]
19. Robust hydrolysis of prostaglandin glycerol esters by human monoacylglycerol lipase (MAGL).
Savinainen JR; Kansanen E; Pantsar T; Navia-Paldanius D; Parkkari T; Lehtonen M; Laitinen T; Nevalainen T; Poso A; Levonen AL; Laitinen JT
Mol Pharmacol; 2014 Nov; 86(5):522-35. PubMed ID: 25140003
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
